Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Stoke Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
12.4
8.78
36.6
184
Research and development
8.37
23.8
32.2
54.2
77.8
82.2
89.1
138
Selling, general and administrative
48.8
67.1
General and administrative
4.41
11.9
20.8
31.9
38.9
41.3
48.8
Operating expenses
12.8
35.7
53
86.1
117
124
138
205
Operating income
-12.8
-35.7
-53
-86.1
-104
-115
-101
-20.6
Interest expense
0.05
0.03
0.01
Interest income
0.27
3.35
0.74
9.96
12.7
13.8
Other non-operating income
0.26
3.35
0.8
0.26
3.29
10.1
12.4
13.7
Income tax
0
Net income
-12.5
-32.3
-52.2
-85.8
-101
-105
-89
-6.89
EBITDA
-12.6
-35.2
-52.2
-85.1
-103
-112
-99.2
-18.8
EPS, basic
-17.65
-1.80
-1.56
-2.34
-2.60
-2.38
-1.65
-0.12
EPS, diluted
-17.65
-1.80
-1.56
-2.34
-2.60
-2.38
-1.65
-0.12
Shares, basic (weighted)
0.71
18
33.5
36.7
38.9
44
54
59.2
Shares, diluted (weighted)
0.71
18
33.5
36.7
38.9
44
54
59.2
Balance sheet
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
105
222
287
145
114
191
128
84.2
Short-term investments
0
74.9
116
9.95
88.9
200
Receivables
1.67
5.94
Other current assets
0.55
3.28
6.44
2.22
2.96
2.56
2.3
4.39
Total current assets
106
226
294
229
244
215
233
306
Property, plant and equipment
1.19
2.51
2.68
4.14
6.68
5.82
3.91
3.15
Lease right-of-use assets
1.12
4.94
4.75
6.61
4.35
3.1
Long-term investments
29.8
106
Total assets
108
229
298
239
256
228
272
418
Accounts payable
1.07
0.75
1.5
2.39
0.77
1.7
2.5
4.94
Deferred revenue
14.9
15.3
19
11.9
Total current liabilities
2.47
4.1
11.4
17.1
31.4
30.8
40.1
57.9
Lease liabilities
0.08
3.53
2.72
4.77
2.45
1.14
Other non-current liabilities
3.95
2.97
4.88
2.48
1.14
Total liabilities
2.47
4.32
11.8
21.1
71.2
68.8
42.5
66
Paid-in capital
131
282
396
414
483
561
720
850
Retained earnings
-25.7
-58
-110
-196
-297
-402
-491
-498
Other comprehensive income
-0.17
-1.18
-0.02
-0.15
0.54
Shareholders' equity
105
224
286
218
185
160
229
352
Total equity
105
224
286
218
185
160
229
352
Total liabilities and equity
108
229
298
239
256
228
272
418
Shares outstanding
0.73
32.9
36.6
36.9
39.4
45.9
54
58.9
Cash flow statement
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-12.5
-32.3
-52.2
-85.8
-101
-105
-89
-6.89
Depreciation and amortization
0.21
0.45
0.89
0.97
1.55
2.47
2.18
1.77
Stock-based compensation
0.24
1.92
5.77
16.5
22.9
25.3
27.5
32.2
Change in receivables
-0.05
-4.27
Change in payables
1.74
0.89
5.2
2.9
-3.53
Cash from operations
-11
-31.1
-42.2
-66.9
-31.9
-81.1
-86.9
45.6
Capital expenditures
-0.94
-1.64
-1.05
-1.2
-3.96
-1.62
-0.2
-0.67
Purchases of investments
-87.2
-201
0
-167
-323
Sales and maturities of investments
12
159
108
60
137
Cash from investing
-0.93
-1.63
-1.05
-76.4
-45.9
106
-107
-187
Stock issued
0.02
0.32
2.84
0.78
0.49
0.37
1.72
8.6
Cash from financing
116
150
108
1.28
46.4
53
131
97.4
Net change in cash
104
117
64.8
-142
-31.3
77.9
-63.2
-43.8
Free cash flow
-11.9
-32.7
-43.3
-68.1
-35.8
-82.7
-87.1
44.9
Income taxes paid
0.57
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $24.80 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-809.7%
Operating income / revenue.
EBITDA margin
-803.4%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-753.6%
Net income / revenue.
FCF margin
-654.9%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-645.2%
Cash from operations / revenue.
Return on equity (ROE)
-60.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-52.8%
Net income / average total assets.
Return on invested capital (ROIC)
-74.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
611.0%
Research and development expense / revenue.
SG&A / revenue
298.7%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
135.7%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
9.8%
Capital expenditures / revenue.
D&A / revenue
6.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
404.5%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
145.9%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
53.9%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
24.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
4.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
54.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
17.8%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
7.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
9.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
15.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
12.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
7.69x
Current assets / current liabilities.
Quick ratio
7.15x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
6.98x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.42
Revenue / diluted weighted shares.
FCF per share
-$2.74
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$2.70
Cash from operations / diluted weighted shares.
Book value per share
$5.54
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
58.0x
Market cap / revenue.
P/B
4.63x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4.63x
Market cap / tangible book value, when positive.
EV/Sales
47.4x
Enterprise value / revenue.
FCF yield
-11.3%
Free cash flow / market cap.
Earnings yield
-13.0%
Net income / market cap (the inverse of P/E).
What was Stoke Therapeutics, Inc.'s revenue in fiscal 2025?
Stoke Therapeutics, Inc. reported revenue of $184.4M for fiscal 2025, 404.5% higher than the year before.
Was Stoke Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $6.9M.
How much free cash flow did Stoke Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $45.6M minus capital expenditures of $670.0K left free cash flow of $44.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.